Shares of FibroBiologics, Inc. (NASDAQ:FBLG – Get Free Report) rose 16% on Thursday . The company traded as high as $11.75 and last traded at $11.01. Approximately 78,924 shares changed hands during trading, a decline of 24% from the average daily volume of 104,478 shares. The stock had previously closed at $9.49.
FibroBiologics Price Performance
The business has a fifty day moving average of $11.36.
FibroBiologics Company Profile
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
See Also
- Five stocks we like better than FibroBiologics
- Find and Profitably Trade Stocks at 52-Week Lows
- Comprehensive PepsiCo Stock Analysis
- P/E Ratio Calculation: How to Assess Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Bear Market Funds to Watch This Year
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
